MBA MD - Synaptogenix CEO Director
| SNPX Stock | USD 2.60 0.03 1.17% |
Insider
MBA MD is CEO Director of Synaptogenix
| Age | 77 |
| Address | 1185 Avenue of the Americas, New York, NY, United States, 10036 |
| Phone | 973 242 0005 |
| Web | https://www.synaptogen.com |
Synaptogenix Management Efficiency
The company has return on total asset (ROA) of (0.1382) % which means that it has lost $0.1382 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.075) %, meaning that it created substantial loss on money invested by shareholders. Synaptogenix's management efficiency ratios could be used to measure how well Synaptogenix manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.2 in 2024. Return On Capital Employed is likely to drop to -0.33 in 2024. Non Current Assets Total is likely to rise to about 610 K in 2024, whereas Total Assets are likely to drop slightly above 28.6 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Claudine Bruck | Annovis Bio | 65 | |
| Raymond MD | INmune Bio | 68 | |
| E Strattan | Cyclo Therapeutics | 78 | |
| Reid McCarthy | Annovis Bio | 66 | |
| Laxminarayan Bhat | Reviva Pharmaceuticals Holdings | 59 | |
| Christopher Barnum | INmune Bio | N/A | |
| David MBA | INmune Bio | 54 | |
| Lise MD | Cyclo Therapeutics | 60 | |
| Narayan Prabhu | Reviva Pharmaceuticals Holdings | 52 | |
| BSc FRCPath | INmune Bio | 59 | |
| Michael Hoffman | Annovis Bio | 69 | |
| Scott Fine | Cyclo Therapeutics | 67 | |
| George Fails | Cyclo Therapeutics | 79 | |
| Jeffrey Tate | Cyclo Therapeutics | 66 | |
| MBA III | Annovis Bio | 56 | |
| Mark White | Annovis Bio | 68 | |
| David Katzoff | Alzamend Neuro | 62 | |
| Lori Gorski | Cyclo Therapeutics | N/A | |
| Stephan Jackman | Alzamend Neuro | 48 | |
Management Performance
| Return On Equity | -0.075 | ||||
| Return On Asset | -0.14 |
Synaptogenix Management Team
Elected by the shareholders, the Synaptogenix's board of directors comprises two types of representatives: Synaptogenix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Synaptogenix. The board's role is to monitor Synaptogenix's management team and ensure that shareholders' interests are well served. Synaptogenix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Synaptogenix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel MD, Chief President | ||
| MBA MD, CEO Director | ||
| Robert Weinstein, Executive CFO |
Synaptogenix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Synaptogenix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.075 | ||||
| Return On Asset | -0.14 | ||||
| Current Valuation | (18.23 M) | ||||
| Shares Outstanding | 1.36 M | ||||
| Shares Owned By Insiders | 1.94 % | ||||
| Shares Owned By Institutions | 0.29 % | ||||
| Number Of Shares Shorted | 5.46 K | ||||
| Price To Book | 0.28 X | ||||
| EBITDA | (8.31 M) | ||||
| Net Income | (6.04 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Synaptogenix Stock Analysis
When running Synaptogenix's price analysis, check to measure Synaptogenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synaptogenix is operating at the current time. Most of Synaptogenix's value examination focuses on studying past and present price action to predict the probability of Synaptogenix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synaptogenix's price. Additionally, you may evaluate how the addition of Synaptogenix to your portfolios can decrease your overall portfolio volatility.